Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia
Clinical trial NCT02827617 · COMPLETED
Trial details
- NCT number
- NCT02827617
- Sponsor
- Oncology Institute of Southern Switzerland
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2016-06-01
- Primary completion
- 2021-08-31
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.